Table 3.
Overall flow of PrEP cascade in pregnant women in antenatal care in 8 clinics (March 2022- September 2023)
| Clinic | HIV antenatal prevalence (2021) | # of ANC visits* | # of HIV tests in pregnant women | # of HIV negative tests in pregnant women | Estimated # HIV-negative pregnant women eligible for PrEP** | # and % PrEP initiated (of HIV-tested) | # and % continued at 1m and 3m |
|---|---|---|---|---|---|---|---|
| MOU/CHC 1 | 13% | 18 947 | 4 477 | 4 425 | 2 766 | 168 (6%) | 39 (23%) |
| MOU/CHC 2 | 34% | 20 534 | 3 763 | 3 653 | 2 283 | 729 (32%) | 280 (38%) |
| MOU/CHC 3 | 10% | 24 610 | 8 603 | 8 534 | 5 334 | 83 (2%) | 33 (40%) |
| Clinic 1 | 28% | 2 378 | 1 121 | 1 112 | 695 | 205 (29%) | 143 (70%) |
| Clinic 2 | 35% | 1 461 | 1 072 | 1 057 | 661 | 147 (22%) | 45 (31%) |
| Clinic 3 | 38% | 1 244 | 816 | 802 | 501 | 84 (17%) | 55 (65%) |
| Clinic 4 | 24% | 1 032 | 794 | 784 | 490 | 45 (9%) | 16 (36%) |
| Clinic 5 | 33% | 398 | 290 | 283 | 177 | 32 (18%) | 6 (19%) |
| Total | 69 752 | 20 466 | 20 183 | 12 614 | 1 493 (12%) | 617 (41%) | |
*
MOU headcounts may include postpartum women attending for the initial postnatal visit and women in labour
**
Estimates of 1.6 HIV tests conducted in antenatal care per CT Metro data from 2022